P2RY12 and myeloid sarcoma: Under this perspective, and consistently with previous findings establishing the role of purinergic receptors in the pathogenesis of both ALS and MS [14, 43], our present work serves this aim, by highlighting the gradual loss of P2Y12 immunoreactivity as an early marker of neuroinflammation and microglia metamorphosis.